Psychedelic Anxiety Trial Succeeds; Depression Drug Fails
Definium Therapeutics reported that its investigational LSD tablet met primary and key secondary endpoints in a second phase III trial for anxiety. In contrast, a phase II trial of a selective M1 receptor inhibitor for major depressive disorder from Contineum and Johnson & Johnson missed its primary outcome. Other psychiatry news included a meta-analysis linking ADHD to higher odds of gastrointestinal issues and a study suggesting adult-diagnosed ADHD may be milder than youth-diagnosed cases.
Definium's lysergide tablet achieved its primary and key secondary goals in a second phase III anxiety trial, signaling momentum for psychedelic-based therapeutics. Separately, the Contineum/J&J M1 receptor inhibitor failed its phase II depression endpoint, underscoring the difficulty of developing novel mechanisms for mood disorders.
ADHD research presented a mixed picture: one meta-analysis found elevated gastrointestinal comorbidity odds, while another study suggested adult-diagnosed cases carry milder clinical and genetic markers than youth diagnoses. Stimulant treatments, especially higher-dose methylphenidate and mixed amphetamine salts, beat placebo on both ADHD symptoms and stimulant-use measures.
These findings may influence clinical practice and public perception. Psychedelic trial success could accelerate regulatory pathways and patient access, while the depression drug failure may temper expectations for rapid innovation. ADHD insights might refine diagnostic criteria and treatment approaches for adults. Postpartum psychosis discussions and celebrity disclosures could reduce stigma and improve screening. The VA burnout data may prompt workforce reforms, and the Romanian hospital fundraiser highlights infrastructure gaps in pediatric mental health care.